









Registered Address: Chemicea Pharmaceuticals Pvt Ltd, Platinum Springs,

Unit No- A- 205&206 Second floor, Plot No: G-6, G-20 to G 24, Taloja- MIDC, Opp. Dena Bank

Navi Mumbai 410208, MH, INDIA. Email- info@chemicea.com Mob- +91 9284897978

## **CERTIFICATE OF ANALYSIS**

Analysis Date: Apr 2025 Re-test Date: Mar 2028

**Product Name: Nilotinib EP Impurity H** 

## **Identification:**

Chemical Name: 4-methyl-N-(3-(5-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-

yl)amino)benzamide

Synonyms : Nilotinib Regio Isomer

CAS Number : 641571-15-5

CAT Number : CP-N11008

Molecular Formula : C28H22F3N7O

Molecular Weight : 529.53

Batch Number : CHEM-NIL-H

Storage Condition : Tightly closed, Inert atmosphere at 2 to 8° C

Shipping condition : All Products are stable to be shipped at room temperature, if specific condition required it is

mention in the COA

## **Analytical Information:**

| Sr. No. | Test               | Result                   |
|---------|--------------------|--------------------------|
| 1)      | Description        | Off White Solid          |
| 2)      | Solubility         | Soluble in Methanol/DMSO |
| 3)      | MASS By LCMS       | Confirm to structure     |
| 4)      | Purity By HPLC     | 98.94%                   |
| 5)      | 1HNMR              | Confirm to structure     |
| 6)      | IR                 | Confirm to structure     |
| 7)      | Weight loss by TGA | 0.4%                     |
| 8)      | Potency by TGA     | 98.54%                   |



**Prepared and Reviewed By** 

Sign of the same

Ms Priyanka Salunkhe (Quality Control)

**Approved By** 



Ms Rohini Gagare (Quality Assurance)

| Note: Product supplied by Chemicea are for R&D purpose only and not for human consumptions. |  |  |  |  |
|---|--|--|--|--|
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |